Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia

被引：3

作者：

Gaut, Daria ^{[1
,8
]}

Oliai, Caspian ^{[1
]}

Boiarsky, Jonathan ^{[1
]}

Zhang, Shiliang ^{[1
]}

Salhotra, Amandeep ^{[2
]}

Azenkot, Tali ^{[3
]}

Kennedy, Vanessa E. ^{[4
]}

Khanna, Vishesh ^{[5
]}

Olmedo Gutierrez, Karla ^{[6
]}

Shukla, Navika ^{[7
]}

Moskoff, Benjamin ^{[3
]}

Park, Gabriel ^{[2
]}

Afkhami, Michelle ^{[2
]}

Patel, Anand ^{[7
]}

Jeyakumar, Deepa ^{[6
]}

Mannis, Gabriel ^{[5
]}

Logan, Aaron C. ^{[4
]}

Jonas, Brian A. ^{[3
]}

Schiller, Gary ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA

[2] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplant, Duarte, CA USA

[3] Univ Calif Davis, Dept Med, Div Hematol Oncol, Sch Med, Sacramento, CA USA

[4] Univ Calif San Francisco, Sch Med, Dept Med, Div Hematol Oncol, San Francisco, CA USA

[5] Stanford Canc Inst, Dept Med, Div Hematol, Stanford, CA USA

[6] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol Oncol, Orange, CA USA

[7] Univ Chicago, Dept Med, Div Hematol Oncol, Chicago, IL USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, 200 UCLA Med Plaza,Suite 120, Los Angeles, CA 90095 USA

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 01期

关键词：

Acute myeloid leukemia; measurable residual disease; consolidation chemotherapy; allogeneic hematopoietic stem cell transplantation; HEMATOPOIETIC-CELL TRANSPLANTATION; MULTIPARAMETER FLOW-CYTOMETRY; COMPLETE REMISSION; OLDER PATIENTS; IMPACT; MRD; AML; HOVON/SAKK; INDUCTION; SURVIVAL;

D O I：

10.1080/10428194.2023.2264426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete remission with detectable MRD post-induction therapy who received standard chemotherapy consolidation. In response to standard intermediate/high-dose cytarabine consolidation therapy, 26 of 60 patients (43.3%) with MRD threshold of detection of at least 0.1% converted to MRD-negative status (undetectable with assay used), and 6 of 47 patients (12.8%) with MRD threshold of detection > 0.1% converted to MRD-negative status. Multivariable logistic regression for patients with MRD threshold of detection of at least 0.1% showed that, when controlling for age, ELN risk category, dose of cytarabine, and use of a combination agent, treatment with 1 cycle of consolidation cytarabine versus >= 2 cycles decreased the odds of conversion of AML to MRD-negative (OR = 0.24, 95% CI 0.07-0.85, p = 0.03).

引用

页码：69 / 77

页数：9

共 28 条

[11] Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations [J].

Freeman, Sylvie D. ;

Hills, Robert K. ;

Virgo, Paul ;

Khan, Naeem ;

Couzens, Steve ;

Dillon, Richard ;

Gilkes, Amanda ;

Upton, Laura ;

Nielsen, Ove Juul ;

Cavenagh, James D. ;

Jones, Gail ;

Khwaja, Asim ;

Cahalin, Paul ;

Thomas, Ian ;

Grimwade, David ;

Burnett, Alan K. ;

Russell, Nigel H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) :1486-+

[12] Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia [J].

Freeman, Sylvie D. ;

Virgo, Paul ;

Couzens, Steve ;

Grimwade, David ;

Russell, Nigel ;

Hills, Robert K. ;

Burnett, Alan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4123-+

[13] Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies [J].

Gaut, Daria ;

Mead, Monica .

LEUKEMIA & LYMPHOMA, 2021, 62 (01) :8-31

[14] 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party [J].

Heuser, Michael ;

Freeman, Sylvie D. ;

Ossenkoppele, Gert J. ;

Buccisano, Francesco ;

Hourigan, Christopher S. ;

Ngai, Lok Lam ;

Tettero, Jesse M. ;

Bachas, Costa ;

Baer, Constance ;

Bene, Marie-Christine ;

Bucklein, Veit ;

Czyz, Anna ;

Denys, Barbara ;

Dillon, Richard ;

Feuring-Buske, Michaela ;

Guzman, Monica L. ;

Haferlach, Torsten ;

Han, Lina ;

Herzig, Julia K. ;

Jorgensen, Jeffrey L. ;

Kern, Wolfgang ;

Konopleva, Marina Y. ;

Lacombe, Francis ;

Libura, Marta ;

Majchrzak, Agata ;

Maurillo, Luca ;

Ofran, Yishai ;

Philippe, Jan ;

Plesa, Adriana ;

Preudhomme, Claude ;

Ravandi, Farhad ;

Roumier, Christophe ;

Subklewe, Marion ;

Thol, Felicitas ;

van de Loosdrecht, Arjan A. ;

van der Reijden, Bert A. ;

Venditti, Adriano ;

Wierzbowska, Agnieszka ;

Valk, Peter J. M. ;

Wood, Brent L. ;

Walter, Roland B. ;

Thiede, Christian ;

Dohner, Konstanze ;

Roboz, Gail J. ;

Cloos, Jacqueline .

BLOOD, 2021, 138 (26) :2753-2767

[15] Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease [J].

Hourigan, Christopher S. ;

Dillon, Laura W. ;

Gui, Gege ;

Logan, Brent R. ;

Fei, Mingwei ;

Ghannam, Jack ;

Li, Yuesheng ;

Licon, Abel ;

Alyea, Edwin P. ;

Bashey, Asad ;

Deeg, H. Joachim ;

Devine, Steven M. ;

Fernandez, Hugo F. ;

Giralt, Sergio ;

Hamadani, Mehdi ;

Howard, Alan ;

Maziarz, Richard T. ;

Porter, David L. ;

Scott, Bart L. ;

Warlick, Erica D. ;

Pasquini, Marcelo C. ;

Horwitz, Mitchell E. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1273-+

[16] Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia [J].

Kern, W ;

Voskova, D ;

Schoch, C ;

Hiddemann, W ;

Schnittger, S ;

Haferlach, T .

BLOOD, 2004, 104 (10) :3078-3085

[17] Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia:: Results from cancer and leukemia group B study 8461 [J].

Marcucci, G ;

Mrózek, K ;

Ruppert, AS ;

Archer, KJ ;

Pettenati, MJ ;

Heerema, NA ;

Carroll, AJ ;

Koduru, PRK ;

Kolitz, JE ;

Sterling, LJ ;

Edwards, CG ;

Anastasi, J ;

Larson, RA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2410-2418

[18] Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML [J].

Murdock, H. Moses ;

Kim, Haesook T. ;

Denlinger, Nathan ;

Vachhani, Pankit ;

Hambley, Bryan ;

Manning, Bryan S. ;

Gier, Shannon ;

Cho, Christina ;

Tsai, Harrison K. ;

McCurdy, Shannon ;

Ho, Vincent T. ;

Koreth, John ;

Soiffer, Robert J. ;

Ritz, Jerome ;

Carroll, Martin P. ;

Vasu, Sumithira ;

Perales, Miguel-Angel ;

Wang, Eunice S. ;

Gondek, Lukasz P. ;

Devine, Steven ;

Alyea, Edwin P., III ;

Lindsley, R. Coleman ;

Gibson, Christopher J. .

BLOOD, 2022, 139 (24) :3546-3557

[19] Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia [J].

Norkin, Maxim ;

Katragadda, Lakshmikanth ;

Zou, Fei ;

Xiong, Sican ;

Chang, Myron ;

Dai, Yunfeng ;

Hsu, Jack W. ;

Moreb, Jan S. ;

Leather, Helen ;

Murthy, Hemant S. ;

Farhadfar, Nosha ;

Li, Ying ;

Hromas, Robert ;

Brown, Randy A. ;

Cogle, Christopher R. ;

Wingard, John R. .

BLOOD CANCER JOURNAL, 2017, 7

[20] Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial [J].

Platzbecker, Uwe ;

Middeke, Jan Moritz ;

Sockel, Katja ;

Herbst, Regina ;

Wolf, Dominik ;

Baldus, Claudia D. ;

Oelschlagel, Uta ;

Mutherig, Anke ;

Fransecky, Lars ;

Noppeney, Richard ;

Bug, Gesine ;

Goetze, Katharina S. ;

Kraemer, Alwin ;

Bochtler, Tilmann ;

Stelljes, Matthias ;

Groth, Christoph ;

Schubert, Antje ;

Mende, Marika ;

Stoelzel, Friedrich ;

Borkmann, Christin ;

Kubasch, Anne Sophie ;

von Bonin, Malte ;

Serve, Hubert ;

Haenel, Mathias ;

Duehrsen, Ulrich ;

Schetelig, Johannes ;

Roellig, Christoph ;

Kramer, Michael ;

Ehninger, Gerhard ;

Bornhaeuser, Martin ;

Thiede, Christian .

LANCET ONCOLOGY, 2018, 19 (12) :1668-1679

← 1 2 3 →